VANI
Vivani Medical, Inc.
Next earnings Aug 11, 2026 · consensus $-0.09 EPS
Last earnings +1.8% on 2026-05-13
$1.20
▲ +5.26%$1.20▼ -4.76%
over 1Y
L $0.94EODHDH $1.87
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.3%
1W+6.2%
1M-6.3%
3M+17.6%
YTD-5.5%
1Y-4.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Mixed signals in the latest filings.
Vivani Medical, Inc. shows $0.00 in FY2025 revenue, and -169.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 |
| Gross profit | $130K | — | — | — | — |
| Operating income | -$13.3M | -$21.2M | -$27.0M | -$24.7M | -$27.6M |
| Net income | -$12.8M | -$13.9M | -$25.7M | -$23.5M | -$26.6M |
| Diluted EPS | — | — | -$0.50 | -$0.43 | -$0.43 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$87.5M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-26.2%
FCF yield-25.1%
Quality & risk
ROIC (est.)-121.4%
Free cash flow-$25.5M
Total debt$2.20M
Net cash$14.0M
Altman Z-Score-4.67 distress
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+42.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-242026-06-26open ↗3Period ending 2026-06-242026-06-26open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-242026-06-25open ↗4Period ending 2026-06-152026-06-16open ↗8-KPeriod ending 2026-06-042026-06-04open ↗SCHEDULE 13D/AFiling2026-05-19open ↗4Period ending 2026-05-152026-05-19open ↗8-KPeriod ending 2026-05-132026-05-13open ↗10-QPeriod ending 2026-03-312026-05-13open ↗
Frequently asked
- Is Vivani Medical, Inc. (VANI) a buy?
- VANI currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is Vivani Medical, Inc.'s quality score?
- VANI scores 32.38461538461539/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001266806, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 2:09:12 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.